<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35339308</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.</ArticleTitle><Pagination><StartPage>A85</StartPage><EndPage>A92</EndPage><MedlinePgn>A85-A92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.03.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00277-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">The global withdrawal of trivalent oral poliovirus vaccine (OPV) (tOPV, containing Sabin poliovirus strains serotypes 1, 2 and 3) from routine immunization, and the introduction of bivalent OPV (bOPV, containing Sabin poliovirus strains serotypes 1 and 3) and trivalent inactivated poliovirus vaccine (IPV) into routine immunization was expected to improve population serologic and mucosal immunity to types 1 and 3 poliovirus, while population mucosal immunity to type 2 poliovirus would decline. However, over the period since tOPV withdrawal, the implementation of preventive bOPV supplementary immunization activities (SIAs) has decreased, while outbreaks of type 2 circulating vaccine derived poliovirus (cVDPV2) have required targeted use of monovalent type 2 OPV (mOPV2).</AbstractText><AbstractText Label="METHODS">We develop a dynamic model of OPV-induced immunity to estimate serotype-specific, district-level immunity for countries in priority regions and characterize changes in immunity since 2016. We account for the changes in routine immunization schedules and varying implementation of preventive and outbreak response SIAs, assuming homogenous coverages of 50% and 80% for SIAs.</AbstractText><AbstractText Label="RESULTS">In areas with strong routine immunization, the switch from tOPV to bOPV has likely resulted in gains in population immunity to types 1 and 3 poliovirus. However, we estimate that improved immunogenicity of new schedules has not compensated for declines in preventive SIAs in areas with weak routine immunization. For type 2 poliovirus, without tOPV in routine immunization or SIAs, mucosal immunity has declined nearly everywhere, while use of mOPV2 has created highly heterogeneous population immunity for which it is important to take into account when responding to cVDPV2 outbreaks.</AbstractText><AbstractText Label="CONCLUSIONS">The withdrawal of tOPV and declining allocations of resources for preventive bOPV SIAs have resulted in reduced immunity in vulnerable areas to types 1 and 3 poliovirus and generally reduced immunity to type 2 poliovirus in the regions studied, assuming homogeneous coverages of 50% and 80% for SIAs. The very low mucosal immunity to type 2 poliovirus generates substantially greater risk for further spread of cVDPV2 outbreaks. Emerging gaps in immunity to all serotypes will require judicious targeting of limited resources to the most vulnerable populations by the Global Polio Eradication Initiative (GPEI).</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voorman</LastName><ForeName>Arend</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA. Electronic address: arend.voorman@gatesfoundation.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Hil</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA; Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation (BMGF), 500 5th Ave N, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennette</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA; Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation (BMGF), 500 5th Ave N, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makam</LastName><ForeName>Jeevan K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>United Nations Children's Fund (UNICEF), 3 United Nations Plaza, New York, NY 10017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F Vertefeuille</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallis</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organization (WHO), Avenue Appia 20, 1202 Genève, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease Modeling</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Population immunity</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>20</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35339308</ArticleId><ArticleId IdType="mid">NIHMS1965784</ArticleId><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.013</ArticleId><ArticleId IdType="pii">S0264-410X(22)00277-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013–2018. Geneva, Switzerland: World Health Organization; 2013.</Citation></Reference><Reference><Citation>World Health Organization. 14th meeting of the global commission for the certification of poliomyelitis eradication (GCC) Bali, Indonesia, 20–21 September, 2015: summary of findings, decisions and recommendations; 2015.</Citation></Reference><Reference><Citation>Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E. A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis 2017;216:S33–9. 10.1093/infdis/jiw550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw550</ArticleId><ArticleId IdType="pmc">PMC5853471</ArticleId><ArticleId IdType="pubmed">28838159</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre M, Wolff CG, Tangermann RH, Chenoweth P, Tallis G, Kamgang JB, et al. Assessing and mitigating the risks for polio outbreaks in polio-free countries — Africa, 2013–2014. Morb Mortal Wkly Rep 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779440</ArticleId><ArticleId IdType="pubmed">25166927</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Lyons HM. Measuring polio immunity to plan immunization activities. Vaccine 2016;34(48):5946–52. 10.1016/j.vaccine.2016.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.017</ArticleId><ArticleId IdType="pmc">PMC5104692</ArticleId><ArticleId IdType="pubmed">27771181</ArticleId></ArticleIdList></Reference><Reference><Citation>Upfill-Brown AM, Lyons HM, Pate MA, Shuaib F, Baig S, Hu H, et al. Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria. BMC Med 2014;12(1). 10.1186/1741-7015-12-92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-12-92</ArticleId><ArticleId IdType="pmc">PMC4066838</ArticleId><ArticleId IdType="pubmed">24894345</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer LD, Safdar RM, Ahmed J, Mahamud A, Khan MM, Gerber S, et al. Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan. BMC Med 2017;15(1). 10.1186/s12916-017-0941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0941-2</ArticleId><ArticleId IdType="pmc">PMC5635525</ArticleId><ArticleId IdType="pubmed">29017491</ArticleId></ArticleIdList></Reference><Reference><Citation>Molodecky NA, Blake IM, Reilly KMO, Wadood MZ, Safdar RM, Wesolowski A, et al. Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis; 2017. p. 1–19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467805</ArticleId><ArticleId IdType="pubmed">28604777</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly KM, Lamoureux C, Molodecky NA, Lyons H, Grassly NC, Tallis G. An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. BMC Infect Dis 2017;17(1). 10.1186/s12879-017-2443-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2443-4</ArticleId><ArticleId IdType="pmc">PMC5446690</ArticleId><ArticleId IdType="pubmed">28549485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Molodecky NA, O’Reilly KM, Wadood MZ, Safdar RM, Etsano A, et al. Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: spatio-temporal modelling of surveillance data. PLoS Med 2016;13(10):e1002140. 10.1371/journal.pmed.1002140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002140</ArticleId><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med 2008;359(16):1666–74. 10.1056/NEJMoa0803259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0803259</ArticleId><ArticleId IdType="pubmed">18923171</ArticleId></ArticleIdList></Reference><Reference><Citation>Upfill-Brown AM, Voorman A, Chabot-Couture G, Shuaib F, Lyons HM. Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria. BMC Med 2016;14:60. 10.1186/s12916-016-0600-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0600-z</ArticleId><ArticleId IdType="pmc">PMC4812602</ArticleId><ArticleId IdType="pubmed">27029535</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly KM, Durry E, ul Islam O, Quddus A, Abid N, Mir TP, et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. The Lancet 2012;380(9840):491–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418593</ArticleId><ArticleId IdType="pubmed">22766207</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007;369(9570):1356–62. 10.1016/S0140-6736(07)60531-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60531-5</ArticleId><ArticleId IdType="pubmed">17448821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, et al. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. Lancet Glob Heal 2014;2(2):e90–7. 10.1016/S2214-109X(13)70168-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70168-2</ArticleId><ArticleId IdType="pubmed">25104665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010;376(9753):1682–8. 10.1016/S0140-6736(10)61230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61230-5</ArticleId><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, Fullman N, Graetz N, et al. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000–2016: a spatial and temporal modelling study. Lancet 2019;393 (10183):1843–55. 10.1016/S0140-6736(19)30226-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30226-0</ArticleId><ArticleId IdType="pmc">PMC6497987</ArticleId><ArticleId IdType="pubmed">30961907</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens FR, Gaughan AE, Linard C, Tatem AJ, Amaral Luís AN. Disaggregating census data for population mapping using Random forests with remotely-sensed and ancillary data. PLoS ONE 2015;10(2):e0107042. 10.1371/journal.pone.0107042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107042</ArticleId><ArticleId IdType="pmc">PMC4331277</ArticleId><ArticleId IdType="pubmed">25689585</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AE, Okayasu H, Nzioki MM, Wadood MZ, Chabot-Couture G, Quddus A, et al. Lot quality assurance sampling to monitor supplemental immunization activity quality: an essential tool for improving performance in polio endemic countries. J Infect Dis 2014;210(suppl_1):S333–40. 10.1093/infdis/jit816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit816</ArticleId><ArticleId IdType="pubmed">25316852</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamu US, Archer WR, Braka F, Damisa E, Siddique A, Baig S, et al. Progress toward poliomyelitis eradication — Nigeria, January 2018–May 2019. MMWR Morb Mortal Wkly Rep 2019;68(29):642–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660103</ArticleId><ArticleId IdType="pubmed">31344023</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991.</Citation><ArticleIdList><ArticleId IdType="pubmed">1845806</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, O’Reilly K, Lyons H, Goel AK, Touray K, Okiror S. Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies. Vaccine 2021. 10.1016/j.vaccine.2021.08.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.08.064</ArticleId><ArticleId IdType="pmc">PMC10109086</ArticleId><ArticleId IdType="pubmed">34483024</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO/UNICEF Estimates of National Immunization Coverage, 2019 revision; 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>